Via Mass Device
“Reports in the United Kingdom say that a 99% accurate COVID-19 antibody test produced by Abbott (NYSE:ABT) won CE Mark approval for use across Europe.”
“The Abbott Park, Ill.-based company, which has a base in Maidenhead, England, expects to have shipped millions of its lab-based tests across Europe by the end of May, according to a report in The Independent.“
“Abbott’s test identifies the IgG protein in bodies that are infected by COVID-19, showing 99% sensitivity 14 days after symptoms were developed in 73 coronavirus-positive patients, according to the report. It also showcased 99% specificity in identifying that 1,070 negative samples did not contain COVID-19 antibodies.”
“According to the report, Abbott is significantly scaling up its European manufacturing for antibody testing while also developing testing for detecting the IgM antibody.”
Learn more about Abbott’s plan to help serve the European market from Mass Device
MAA COVID-19 INFORMATION DISCLAIMER:
The Medical Alley Association is providing COVID-19 related information, including the “COVID-19 Resource Connect” feature on its website and summaries of laws, executive orders, and government programs that may be of interest to members, as a public service. The Medical Alley Association makes no representations, guarantees, or warranties as to the accuracy, completeness, currency, or suitability of the COVID-19 related information provided by the Medical Alley Association on its website, in newsletters, or in any other communications. The Medical Alley Association specifically disclaims any and all liability for any claims or damages that may result from providing COVID-19 related information online or in other communications or linking to third party websites or other sources of information. The Medical Alley Association makes no effort to independently verify, and does not exert editorial control over, information provided by third parties.
The Medical Alley Association does not endorse any of the products, vendors, consultants, or documentation referenced in, or connected to parties through, the COVID-19 Resource Connect feature or via email or other communications.
